DE602007013648D1 - Tartratsalz aus Isofagomin und Verwendungsverfahren dafür - Google Patents
Tartratsalz aus Isofagomin und Verwendungsverfahren dafürInfo
- Publication number
- DE602007013648D1 DE602007013648D1 DE602007013648T DE602007013648T DE602007013648D1 DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1 DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 T DE602007013648 T DE 602007013648T DE 602007013648 D1 DE602007013648 D1 DE 602007013648D1
- Authority
- DE
- Germany
- Prior art keywords
- isofagomine
- salt
- tartrate salt
- gaucher disease
- isofagomine tartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003892 tartrate salts Chemical class 0.000 title abstract 2
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 title 1
- ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80802006P | 2006-05-24 | 2006-05-24 | |
| US89071907P | 2007-02-20 | 2007-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007013648D1 true DE602007013648D1 (de) | 2011-05-19 |
Family
ID=38462442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602007013648T Active DE602007013648D1 (de) | 2006-05-24 | 2007-05-23 | Tartratsalz aus Isofagomin und Verwendungsverfahren dafür |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7501439B2 (de) |
| EP (1) | EP1860101B1 (de) |
| JP (1) | JP5292605B2 (de) |
| AT (1) | ATE504570T1 (de) |
| AU (1) | AU2007202359B2 (de) |
| BR (1) | BRPI0706114A2 (de) |
| CA (1) | CA2590122C (de) |
| DE (1) | DE602007013648D1 (de) |
| DK (1) | DK1860101T3 (de) |
| IL (1) | IL183415A (de) |
| MX (1) | MX2007006175A (de) |
| PL (1) | PL1860101T3 (de) |
| PT (1) | PT1860101E (de) |
| WO (1) | WO2007140212A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101541172A (zh) * | 2005-06-08 | 2009-09-23 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| PT2040548E (pt) * | 2006-06-23 | 2012-08-02 | Amicus Therapeutics Inc | Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase |
| JP5441894B2 (ja) | 2007-05-22 | 2014-03-12 | アミカス セラピューティックス インコーポレイテッド | イソファゴミンおよびその誘導体を製造する新規な方法 |
| MX2010008835A (es) | 2008-02-12 | 2010-10-20 | Amicus Therapeutics Inc | Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades. |
| CN102245180A (zh) * | 2008-11-14 | 2011-11-16 | 帕金森氏病研究院 | 用于治疗改变的α-突触核蛋白功能的组合物和方法 |
| RU2733466C2 (ru) | 2009-07-28 | 2020-10-01 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| DK2490532T3 (en) | 2009-10-19 | 2017-02-27 | Amicus Therapeutics Inc | Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System |
| PT2490533E (pt) * | 2009-10-19 | 2016-01-13 | Amicus Therapeutics Inc | Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico |
| SMT201900280T1 (it) | 2011-05-12 | 2019-07-11 | Proteostasis Therapeutics Inc | Regolatori di proteostasi |
| JP6061922B2 (ja) * | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
| JP2015504919A (ja) | 2012-01-25 | 2015-02-16 | プロテオステイシス セラピューティクス，インコーポレイテッド | プロテアソーム活性を調節する化合物 |
| KR20140138850A (ko) | 2012-03-02 | 2014-12-04 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법 |
| WO2013148103A1 (en) | 2012-03-27 | 2013-10-03 | Amicus Therapeutics, Inc. | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system |
| EP2831039A1 (de) | 2012-03-28 | 2015-02-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Salicylsäurederivate als glucocerebrosidase-aktivatoren |
| EP3318277A1 (de) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen |
| DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
| AR113797A1 (es) * | 2017-10-26 | 2020-06-10 | Shire Human Genetic Therapies | Formulaciones que comprenden glucocerebrosidasa e isofagomina |
| MA53014A (fr) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics Inc | Composés améliorant l'activité du protéasome |
| JP7551087B2 (ja) | 2018-06-27 | 2024-09-17 | キネタ， インコーポレイテッド | プロテアソーム活性増強化合物 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| CN113906012A (zh) * | 2019-04-25 | 2022-01-07 | 武田药品工业有限公司 | 异法戈明盐、使用方法和调配物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844102A (en) * | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en active Application Filing
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 EP EP07252109A patent/EP1860101B1/de not_active Not-in-force
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7501439B2 (en) | 2009-03-10 |
| IL183415A (en) | 2012-03-29 |
| PL1860101T3 (pl) | 2011-10-31 |
| CA2590122C (en) | 2015-03-31 |
| JP5292605B2 (ja) | 2013-09-18 |
| EP1860101A1 (de) | 2007-11-28 |
| JP2007314540A (ja) | 2007-12-06 |
| BRPI0706114A2 (pt) | 2008-11-18 |
| US7863453B2 (en) | 2011-01-04 |
| US20090176830A1 (en) | 2009-07-09 |
| DK1860101T3 (da) | 2011-07-25 |
| WO2007140212A2 (en) | 2007-12-06 |
| IL183415A0 (en) | 2007-09-20 |
| WO2007140212A3 (en) | 2008-12-24 |
| PT1860101E (pt) | 2011-07-12 |
| US20070281975A1 (en) | 2007-12-06 |
| MX2007006175A (es) | 2009-02-16 |
| AU2007202359B2 (en) | 2012-02-16 |
| CA2590122A1 (en) | 2007-11-24 |
| ATE504570T1 (de) | 2011-04-15 |
| EP1860101B1 (de) | 2011-04-06 |
| AU2007202359A1 (en) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007013648D1 (de) | Tartratsalz aus Isofagomin und Verwendungsverfahren dafür | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| ZA200804030B (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| RS52754B (en) | MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT | |
| PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
| NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| NO20070470L (no) | Sammensetninger og fremgangsmater for behandling av dyslipidemi | |
| NO20085068L (no) | Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| DE602006013271D1 (de) | Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen | |
| NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| DE602005017503D1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| DE502006003194D1 (de) | Salze substituierter allophansäureester und deren verwendung in arzneimitteln | |
| ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| ATE441632T1 (de) | Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| EA201001773A1 (ru) | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина | |
| UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
| ATE440836T1 (de) | Verbindungen | |
| MX2009003974A (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. | |
| ATE546159T1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης |